{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:42:01Z","timestamp":1784662921362,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01706-x","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T03:16:53Z","timestamp":1755141413000},"page":"1131-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adoptive T-Cell Therapy in Sarcomas"],"prefix":"10.1007","volume":"27","author":[{"given":"Monika","family":"Kucharczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1706_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejca.2012.09.011","volume":"49","author":"CA Stiller","year":"2013","unstructured":"Stiller CA, et al. Descriptive epidemiology of sarcomas in europe: report from the RARECARE project. Eur J Cancer. 2013;49:684\u201395.","journal-title":"Eur J Cancer"},{"key":"1706_CR2","doi-asserted-by":"publisher","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","volume":"16","author":"G De Pinieux","year":"2021","unstructured":"De Pinieux G, et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE. 2021;16:e0246958.","journal-title":"PLoS ONE"},{"key":"1706_CR3","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/annonc\/mdr610","volume":"23","author":"I Ray-Coquard","year":"2012","unstructured":"Ray-Coquard I, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol. 2012;23:2442\u20139.","journal-title":"Ann Oncol"},{"key":"1706_CR4","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cncr.28733","volume":"120","author":"P Youn","year":"2014","unstructured":"Youn P, Milano MT, Constine LS, Travis LB. Long-term cause\u2010specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: A population\u2010based study of 28,844 patients. Cancer. 2014;120:2334\u201342.","journal-title":"Cancer"},{"key":"1706_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397\u2013410.","journal-title":"Lancet Oncol"},{"key":"1706_CR6","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"WD Tap","year":"2020","unstructured":"Tap WD, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323:1266.","journal-title":"JAMA"},{"key":"1706_CR7","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, et al. Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32:1348\u201365.","journal-title":"Ann Oncol"},{"key":"1706_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/cncr.25538","volume":"117","author":"A Italiano","year":"2011","unstructured":"Italiano A, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049\u201354.","journal-title":"Cancer"},{"key":"1706_CR9","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/pbc.25963","volume":"63","author":"TA Marko","year":"2016","unstructured":"Marko TA, Diessner BJ, Spector LG. Prevalence of metastasis at diagnosis of osteosarcoma: an international comparison. Pediatr Blood Cancer. 2016;63:1006\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"1706_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/jso.24889","volume":"117","author":"BM Verbeek","year":"2018","unstructured":"Verbeek BM, et al. Synovial sarcoma of the shoulder: A series of 14 cases. J Surg Oncol. 2018;117:788\u201396.","journal-title":"J Surg Oncol"},{"key":"1706_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/annonc\/mdq394","volume":"22","author":"AH Krieg","year":"2011","unstructured":"Krieg AH, et al. Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol. 2011;22:458\u201367.","journal-title":"Ann Oncol"},{"key":"1706_CR12","volume-title":"Ewing sarcoma. In StatPearls","author":"S Durer","year":"2025","unstructured":"Durer S, Gasalberti DP, Shaikh H. Ewing sarcoma. In StatPearls. Treasure Island (FL): StatPearls Publishing; 2025."},{"key":"1706_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023;389:911\u201321.","journal-title":"N Engl J Med"},{"key":"1706_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1706_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","volume":"28","author":"A Italiano","year":"2022","unstructured":"Italiano A, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28:1199\u2013206.","journal-title":"Nat Med"},{"key":"1706_CR16","doi-asserted-by":"publisher","first-page":"1414884","DOI":"10.3389\/fimmu.2024.1414884","volume":"15","author":"B Jiang","year":"2024","unstructured":"Jiang B, Wu Z, Zhang Y, Yang X. Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis. Front Immunol. 2024;15:1414884.","journal-title":"Front Immunol"},{"key":"1706_CR17","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-19-3416","volume":"26","author":"L Chen","year":"2020","unstructured":"Chen L, et al. The immunosuppressive niche of Soft-Tissue sarcomas is sustained by Tumor-Associated macrophages and characterized by intratumoral tertiary lymphoid structures. Clin Cancer Res. 2020;26:4018\u201330.","journal-title":"Clin Cancer Res"},{"key":"1706_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers17010010","volume":"17","author":"L Mavroeidis","year":"2024","unstructured":"Mavroeidis L, Napolitano A, Huang P, Jones RL. Novel therapeutics in soft tissue sarcoma. Cancers. 2024;17:10.","journal-title":"Cancers"},{"key":"1706_CR19","doi-asserted-by":"publisher","first-page":"203636132412907","DOI":"10.1177\/20363613241290788","volume":"16","author":"F Kalofonou","year":"2024","unstructured":"Kalofonou F, et al. The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic Myxofibrosarcoma. Rare Tumors. 2024;16:20363613241290788.","journal-title":"Rare Tumors"},{"key":"1706_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2147\/CMAR.S237300","volume":"12","author":"Z Tian","year":"2020","unstructured":"Tian Z, et al. Safety and efficacy of PD-1 inhibitors plus chemotherapy in advanced soft tissue sarcomas: A retrospective study. Cancer Manag Res. 2020;12:1339\u201346.","journal-title":"Cancer Manag Res"},{"key":"1706_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","journal-title":"Lancet Oncol"},{"key":"1706_CR22","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","volume":"404","author":"YM Mowery","year":"2024","unstructured":"Mowery YM, et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet. 2024;404:2053\u201364.","journal-title":"Lancet"},{"key":"1706_CR23","doi-asserted-by":"publisher","first-page":"11516","DOI":"10.1200\/JCO.2024.42.16_suppl.11516","volume":"42","author":"A Italiano","year":"2024","unstructured":"Italiano A, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A phase 2 trial of regorafenib combined with avelumab. JCO. 2024;42:11516\u201311516.","journal-title":"JCO"},{"key":"1706_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-21-0878","volume":"28","author":"AS Singh","year":"2022","unstructured":"Singh AS, et al. A randomized phase II study of nivolumab monotherapy or nivolumab combined with ipilimumab in patients with advanced Gastrointestinal stromal tumors. Clin Cancer Res. 2022;28:84\u201394.","journal-title":"Clin Cancer Res"},{"key":"1706_CR25","doi-asserted-by":"publisher","first-page":"100407","DOI":"10.1016\/j.iotech.2023.100407","volume":"20","author":"M Anastasiou","year":"2023","unstructured":"Anastasiou M, et al. Immune checkpoint inhibitors in sarcomas: a systematic review. Immuno-Oncology Technol. 2023;20:100407.","journal-title":"Immuno-Oncology Technol"},{"key":"1706_CR26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, et al. IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107\u201311.","journal-title":"Nature"},{"key":"1706_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/1097-0142(196611)19:11<1743::AID-CNCR2820191143>3.0.CO;2-U","volume":"19","author":"CM Southam","year":"1966","unstructured":"Southam CM, Brunschwig A, Levin AG, Dizon QS. Effect of leukocytes on transplantability of human cancer. Cancer. 1966;19:1743\u201353.","journal-title":"Cancer"},{"key":"1706_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/cancers13040743","volume":"13","author":"A Titov","year":"2021","unstructured":"Titov A, et al. Adoptive immunotherapy beyond CAR T-Cells. Cancers. 2021;13:743.","journal-title":"Cancers"},{"key":"1706_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","volume":"3","author":"WY Ho","year":"2003","unstructured":"Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003;3:431\u20137.","journal-title":"Cancer Cell"},{"key":"1706_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"A-M Tsimberidou","year":"2021","unstructured":"Tsimberidou A-M, et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021;14:102.","journal-title":"J Hematol Oncol"},{"key":"1706_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/mrd.1080380215","volume":"38","author":"M Janitz","year":"1994","unstructured":"Janitz M, et al. Analysis of mRNA for class I HLA on human gametogenic cells. Mol Reprod Devel. 1994;38:231\u20137.","journal-title":"Mol Reprod Devel"},{"key":"1706_CR32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/cells12060926","volume":"12","author":"DS Nin","year":"2023","unstructured":"Nin DS, Deng L-W. Biology of Cancer-Testis antigens and their therapeutic implications in Cancer. Cells. 2023;12:926.","journal-title":"Cells"},{"key":"1706_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","volume":"61","author":"K Iura","year":"2017","unstructured":"Iura K, et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol. 2017;61:130\u20139.","journal-title":"Hum Pathol"},{"key":"1706_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00428-017-2206-z","volume":"471","author":"K Iura","year":"2017","unstructured":"Iura K, et al. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1. Virchows Arch. 2017;471:383\u201392.","journal-title":"Virchows Arch"},{"key":"1706_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, et al. Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A*02 + patients: a phase 1 trial. Nat Med. 2023;29:104\u201314.","journal-title":"Nat Med"},{"key":"1706_CR36","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403:1460\u201371.","journal-title":"Lancet"},{"key":"1706_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1054\/bjoc.2000.1251","volume":"83","author":"E Schultz-Thater","year":"2000","unstructured":"Schultz-Thater E, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer. 2000;83:204\u20138.","journal-title":"Br J Cancer"},{"key":"1706_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molonc.2012.11.004","volume":"7","author":"P-F Cartron","year":"2013","unstructured":"Cartron P-F, Blanquart C, Hervouet E, Gregoire M, Vallette FM. HDAC1-mSin3a\u2010NCOR1, Dnmt3b\u2010HDAC1\u2010Egr1 and Dnmt1\u2010PCNA\u2010UHRF1\u2010G9a regulate the NY\u2010ESO1 gene expression. Mol Oncol. 2013;7:452\u201363.","journal-title":"Mol Oncol"},{"key":"1706_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/modpathol.2012.133","volume":"26","author":"JA Hemminger","year":"2013","unstructured":"Hemminger JA, et al. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol. 2013;26:282\u20138.","journal-title":"Mod Pathol"},{"key":"1706_CR40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2014.155","volume":"28","author":"M Endo","year":"2015","unstructured":"Endo M, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015;28:587\u201395.","journal-title":"Mod Pathol"},{"key":"1706_CR41","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/modpathol.2013.244","volume":"27","author":"JA Hemminger","year":"2014","unstructured":"Hemminger JA, et al. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol. 2014;27:1238\u201345.","journal-title":"Mod Pathol"},{"key":"1706_CR42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01466","author":"S D\u2019Angelo","year":"2025","unstructured":"D\u2019Angelo S, et al. Letetresgene autoleucel in advanced\/metastatic myxoid\/round cell liposarcoma. JCO JCO-24-01466. 2025. https:\/\/doi.org\/10.1200\/JCO-24-01466.","journal-title":"JCO JCO-24-01466"},{"key":"1706_CR43","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov. 2018;8:944\u201357.","journal-title":"Cancer Discov"},{"key":"1706_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","volume":"7","author":"I Ramachandran","year":"2019","unstructured":"Ramachandran I, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunotherapy cancer. 2019;7:276.","journal-title":"J Immunotherapy cancer"},{"key":"1706_CR45","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers17081302","volume":"17","author":"JJ Fradin","year":"2025","unstructured":"Fradin JJ, Charlson JA. Review of adoptive cellular therapies for the treatment of sarcoma. Cancers. 2025;17:1302.","journal-title":"Cancers"},{"key":"1706_CR46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sinica B. 2018;8:539\u201351.","journal-title":"Acta Pharm Sinica B"},{"key":"1706_CR47","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"M-R Benmebarek","year":"2019","unstructured":"Benmebarek M-R, et al. Killing mechanisms of chimeric antigen receptor (CAR) T cells. IJMS. 2019;20:1283.","journal-title":"IJMS"},{"key":"1706_CR48","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/jim-2020-001290","volume":"68","author":"S Atrash","year":"2020","unstructured":"Atrash S, Bano K, Harrison B, Abdallah A-O. Car-T treatment for hematological malignancies. J Investig Med. 2020;68:956\u201364.","journal-title":"J Investig Med"},{"key":"1706_CR49","first-page":"1","volume":"2020","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, et al. CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res. 2020;2020:1\u201311.","journal-title":"J Immunol Res"},{"key":"1706_CR50","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.3390\/ijms20205010","volume":"20","author":"M-K Song","year":"2019","unstructured":"Song M-K, Park B-B, Uhm J-E. Resistance mechanisms to CAR T-Cell therapy and overcoming strategy in B-Cell hematologic malignancies. IJMS. 2019;20:5010.","journal-title":"IJMS"},{"key":"1706_CR51","doi-asserted-by":"publisher","first-page":"107419","DOI":"10.1016\/j.pharmthera.2019.107419","volume":"205","author":"SJ Bagley","year":"2020","unstructured":"Bagley SJ, O\u2019Rourke DM. Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions. Pharmacol Ther. 2020;205:107419.","journal-title":"Pharmacol Ther"},{"key":"1706_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1706_CR53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells14050320","volume":"14","author":"B Zhang","year":"2025","unstructured":"Zhang B, Wu J, Jiang H, Zhou M. Strategies to overcome antigen heterogeneity in CAR-T cell therapy. Cells. 2025;14:320.","journal-title":"Cells"},{"key":"1706_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/curroncol32020079","volume":"32","author":"I Klabukov","year":"2025","unstructured":"Klabukov I, et al. Tumor-Associated extracellular matrix Obstacles for CAR-T cell therapy: approaches to overcoming. Curr Oncol. 2025;32:79.","journal-title":"Curr Oncol"},{"key":"1706_CR55","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","volume":"10","author":"S Sakaguchi","year":"2010","unstructured":"Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490\u2013500.","journal-title":"Nat Rev Immunol"},{"key":"1706_CR56","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","volume":"9","author":"MM D\u2019Aloia","year":"2018","unstructured":"D\u2019Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9:282.","journal-title":"Cell Death Dis"},{"key":"1706_CR57","doi-asserted-by":"publisher","first-page":"114890","DOI":"10.1016\/j.biopha.2023.114890","volume":"163","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K. B7-H3 immunoregulatory roles in cancer. Biomed Pharmacother. 2023;163:114890.","journal-title":"Biomed Pharmacother"},{"key":"1706_CR58","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1186\/s12885-024-13061-4","volume":"24","author":"MM Lynch","year":"2024","unstructured":"Lynch MM, et al. B7-H3 is widely expressed in soft tissue sarcomas. BMC Cancer. 2024;24:1336.","journal-title":"BMC Cancer"},{"key":"1706_CR59","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0726","volume":"21","author":"S Zhang","year":"2022","unstructured":"Zhang S, et al. B7-H3 specific CAR T cells for the naturally occurring, spontaneous canine sarcoma model. Mol Cancer Ther. 2022;21:999\u20131009.","journal-title":"Mol Cancer Ther"},{"key":"1706_CR60","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, et al. CAR T cells targeting B7-H3, a Pan-Cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25:2560\u201374.","journal-title":"Clin Cancer Res"},{"key":"1706_CR61","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fonc.2019.00537","volume":"9","author":"DL Casey","year":"2019","unstructured":"Casey DL, Lin T-Y, Cheung N-KV. Exploiting signaling pathways and immune targets beyond the standard of care for ewing sarcoma. Front Oncol. 2019;9:537.","journal-title":"Front Oncol"},{"key":"1706_CR62","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","volume":"172","author":"P Hingorani","year":"2022","unstructured":"Hingorani P, et al. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the children\u2019s oncology group. Eur J Cancer. 2022;172:264\u201375.","journal-title":"Eur J Cancer"},{"key":"1706_CR63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska S, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024;42:35\u2013e518.","journal-title":"Cancer Cell"},{"key":"1706_CR64","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5:880\u201394.","journal-title":"Nat Cancer"},{"key":"1706_CR65","doi-asserted-by":"publisher","first-page":"153303382513342","DOI":"10.1177\/15330338251334209","volume":"24","author":"B Pei","year":"2025","unstructured":"Pei B, Peng S, Chen W, Lai L, Zhou F. Combining cetuximab and immunotherapy for treating mss\/pmmr colorectal cancer: current evidence and challenges. Technol Cancer Res Treat. 2025;24:15330338251334209.","journal-title":"Technol Cancer Res Treat"},{"key":"1706_CR66","doi-asserted-by":"publisher","first-page":"105867","DOI":"10.1016\/j.oraloncology.2022.105867","volume":"129","author":"C Haist","year":"2022","unstructured":"Haist C, et al. Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas. Oral Oncol. 2022;129:105867.","journal-title":"Oral Oncol"},{"key":"1706_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","volume":"14","author":"H Lin","year":"2024","unstructured":"Lin H, et al. Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control. Blood Cancer J. 2024;14:98.","journal-title":"Blood Cancer J"},{"key":"1706_CR68","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so Far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1706_CR69","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-16-2138","volume":"23","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, et al. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-Modified T cells. Clin Cancer Res. 2017;23:3499\u2013509.","journal-title":"Clin Cancer Res"},{"key":"1706_CR70","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14712598.2022.2064711","volume":"22","author":"JS Granh\u00f8j","year":"2022","unstructured":"Granh\u00f8j JS, et al. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opin Biol Ther. 2022;22:627\u201341.","journal-title":"Expert Opin Biol Ther"},{"key":"1706_CR71","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14:4160.","journal-title":"Cancers"},{"key":"1706_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/0284186X.2023.2172688","volume":"62","author":"H Nystr\u00f6m","year":"2023","unstructured":"Nystr\u00f6m H, J\u00f6nsson M, Nilbert M, Carneiro A. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells. Acta Oncol. 2023;62:33\u20139.","journal-title":"Acta Oncol"},{"key":"1706_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","volume":"21","author":"S Klobuch","year":"2024","unstructured":"Klobuch S, Seijkens TTP, Schumacher TN, Haanen JB. A. G. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024;21:173\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"1706_CR74","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang Y. Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335\u20137.","journal-title":"J Clin Invest"},{"key":"1706_CR75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/intimm\/dxaa046","volume":"33","author":"A Kumar","year":"2021","unstructured":"Kumar A, Chamoto K. Immune metabolism in PD-1 blockade-based cancer immunotherapy. Int Immunol. 2021;33:17\u201326.","journal-title":"Int Immunol"},{"key":"1706_CR76","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.jbo.2020.100332","volume":"25","author":"C Wang","year":"2020","unstructured":"Wang C, Li M, Wei R, Wu J. Adoptive transfer of TILs plus anti-PD1 therapy: an alternative combination therapy for treating metastatic osteosarcoma. J Bone Oncol. 2020;25:100332.","journal-title":"J Bone Oncol"},{"key":"1706_CR77","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.4155\/fmc-2017-0088","volume":"9","author":"B Sveinbj\u2298rnsson","year":"2017","unstructured":"Sveinbj\u2298rnsson B, Camilio KA, Haug BE, Rekdal \u00d8. LTX-315: A First-In-Class oncolytic peptide that reprograms the tumor microenvironment. Future Med Chem. 2017;9:1339\u201344.","journal-title":"Future Med Chem"},{"key":"1706_CR78","doi-asserted-by":"publisher","first-page":"2290900","DOI":"10.1080\/2162402X.2023.2290900","volume":"13","author":"M Nielsen","year":"2024","unstructured":"Nielsen M, et al. LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma. OncoImmunology. 2024;13:2290900.","journal-title":"OncoImmunology"},{"key":"1706_CR79","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.3390\/ijms241512317","volume":"24","author":"W Wei","year":"2023","unstructured":"Wei W, Chen Z-N, Wang K. CRISPR\/Cas9: A powerful strategy to improve CAR-T cell persistence. IJMS. 2023;24:12317.","journal-title":"IJMS"},{"key":"1706_CR80","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou E, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26:559\u201370.","journal-title":"Lancet Oncol"},{"key":"1706_CR81","doi-asserted-by":"publisher","first-page":"1557006","DOI":"10.3389\/fimmu.2025.1557006","volume":"16","author":"Y Jin","year":"2025","unstructured":"Jin Y, et al. Anti-CD137 agonist antibody\u2013independent and clinically feasible Preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. Front Immunol. 2025;16:1557006.","journal-title":"Front Immunol"},{"key":"1706_CR82","doi-asserted-by":"publisher","first-page":"e2338612","DOI":"10.1001\/jamanetworkopen.2023.38612","volume":"6","author":"T Olivier","year":"2023","unstructured":"Olivier T, Haslam A, Tuia J, Prasad V. Eligibility for human leukocyte Antigen\u2013Based therapeutics by race and ethnicity. JAMA Netw Open. 2023;6:e2338612.","journal-title":"JAMA Netw Open"},{"key":"1706_CR83","doi-asserted-by":"publisher","unstructured":"Patel N, Carroll C, Culver K, Pokras S. 899 population coverage of HLA-A*02:01, *02:05, *02:06 across selected cancer types in the united States. Regular and young investigator award abstracts A943\u2013A943. BMJ Publishing Group Ltd; 2021. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.899.","DOI":"10.1136\/jitc-2021-SITC2021.899"},{"key":"1706_CR84","doi-asserted-by":"publisher","first-page":"26851","DOI":"10.1038\/s41598-024-75140-7","volume":"14","author":"V Karuppiah","year":"2024","unstructured":"Karuppiah V, et al. Broadening alloselectivity of T cell receptors by structure guided engineering. Sci Rep. 2024;14:26851.","journal-title":"Sci Rep"},{"key":"1706_CR85","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","volume":"22","author":"EK Moon","year":"2016","unstructured":"Moon EK, et al. Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer. Clin Cancer Res. 2016;22:436\u201347.","journal-title":"Clin Cancer Res"},{"key":"1706_CR86","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.iotech.2024.100715","volume":"24","author":"I Olivera","year":"2024","unstructured":"Olivera I, Etxeberria I, Luri-Rey C, Molero-Glez P, Melero I. Regional and intratumoral adoptive T-cell therapy. Immuno-Oncology Technol. 2024;24:100715.","journal-title":"Immuno-Oncology Technol"},{"key":"1706_CR87","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, et al. Stereotactic radiation therapy augments antigen-Specific PD-1\u2013Mediated antitumor immune responses via Cross-Presentation of tumor antigen. Cancer Immunol Res. 2015;3:345\u201355.","journal-title":"Cancer Immunol Res"},{"key":"1706_CR88","doi-asserted-by":"crossref","unstructured":"Lam, P. Y. et al. Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2\u2010targeted CAR. Clinical & Translational Med 15, e70140 (2025).","DOI":"10.1002\/ctm2.70140"},{"key":"1706_CR89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13569-017-0077-3","volume":"7","author":"J Roszik","year":"2017","unstructured":"Roszik J, et al. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017;7:11.","journal-title":"Clin Sarcoma Res"},{"key":"1706_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03650-6","author":"M Wermke","year":"2025","unstructured":"Wermke M, et al. Autologous T cell therapy for PRAME + advanced solid tumors in HLA-A*02 + patients: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03650-6.","journal-title":"Nat Med"},{"key":"1706_CR91","doi-asserted-by":"crossref","unstructured":"Kirtane K et al. Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial. JCO 43, (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2677"},{"key":"1706_CR92","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615:507\u201316.","journal-title":"Nature"},{"key":"1706_CR93","doi-asserted-by":"publisher","first-page":"1490911","DOI":"10.3389\/fimmu.2024.1490911","volume":"15","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Smith R. Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol. 2024;15:1490911.","journal-title":"Front Immunol"},{"key":"1706_CR94","doi-asserted-by":"publisher","first-page":"1303935","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, et al. Lymphodepletion\u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935.","journal-title":"Front Immunol"},{"key":"1706_CR95","doi-asserted-by":"publisher","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol. 2022;13:879608.","journal-title":"Front Immunol"},{"key":"1706_CR96","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","volume":"31","author":"W Xiao","year":"2024","unstructured":"Xiao W, et al. FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Ther. 2024;31:1571\u201384.","journal-title":"Cancer Gene Ther"},{"key":"1706_CR97","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25:947\u201353.","journal-title":"Nat Med"},{"key":"1706_CR98","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/CCO.0000000000000843","volume":"34","author":"P Mahalingam","year":"2022","unstructured":"Mahalingam P, et al. Immunotherapy of sarcomas with modified T cells. Curr Opin Oncol. 2022;34:362\u201370.","journal-title":"Curr Opin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01706-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01706-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01706-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:04:19Z","timestamp":1760148259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01706-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":98,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01706-x","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Robin L Jones: consulting or advisory role: Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, Pharmamar, Springworks, SynOx, Tracon, Upto Date; research funding: MSD, GSK. Monika Kucharczyk, Emine Hatipoglu and Paul Huang declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}